title: [Adverse Events of Sublingual Immunotherapy in 207 Patients with Japanese Cedar Pollinosis].
abstract: Sublingual immunotherapy (SLIT) for Japanese cedar pollinosis is effective, however, caution must be exercised against allergen-specific adverse events (AEs) during SLIT.
  
  
  OBJECTIVE
  The purpose of this study was to clarify the AEs of SLIT in a large cohort of patients with Japanese cedar pollinosis.
  
  
  METHODS
  We conducted a detailed survey, by both questionnaires and direct interviews, of 207 patients receiving SLIT at our clinic.
  
  
  RESULTS
  Eighty-four of the 207 patients (40.5%) developed AEs, with AEs involving the oral cavity and throat being the most common (56 patients; 27.1%). Sixteen patients (7.9%) had local mucosal swelling, but the swelling resolved in all the cases. Other allergen-induced symptoms such as nasal symptoms (29 events, 14.0%), eye symptoms (14 events, 6.8%) and ear symptoms (20 events, 9.7%) were also recognized. All the AEs were minor, and discontinuation of SLIT was not necessitated in any of the patients because of AEs. There were 52 AEs (25.0%) in the up-dose phase and 61 AEs (29.3%) in the maintenance phase. However, only 4 of the 161 patients (2.5%) developed AEs during the pollen season. Most AEs developing during the maintenance phase occurred in the first few weeks. In 60% of the cases, the AEs disappeared within 2 weeks, and in 6.0% (5 events), they persisted for longer than 2 months. There were no age-or sex-related differences in the prevalence of cedar pollen-specific IgE, or in the adherence to the treatment.
  
  
  CONCLUSIONS
  AEs in SLIT were shown in many patients, however, the severity of AEs was mild and no events interfered SLIT.
authors.forename: Yukiko
authors.initials: Y
authors.lastname: Ogawa
authors.forename: Atsushi
authors.initials: A
authors.lastname: Yuta
authors.forename: Masahiko
authors.initials: M
authors.lastname: Arikata
authors.forename: Hideaki
authors.initials: H
authors.lastname: Kozaki
authors.forename: Nobuo
authors.initials: N
authors.lastname: Ohta
authors.forename: Yusuke
authors.initials: Y
authors.lastname: Suzuki
authors.forename: Takeshi
authors.initials: T
authors.lastname: Shimizu
mesh_terms: D000286:Administration, Sublingual; D000328:Adult; D000485:Allergens / Q000008:administration & dosage*; D002648:Child; D032485:Cryptomeria / Q000276:immunology*; D005260:Female; D006801:Humans; D007167:Immunotherapy / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D006255:Rhinitis, Allergic, Seasonal / Q000276:immunology / Q000628:therapy*
chemical_list: D000485:Allergens